Newborn Screening for Pompe Disease: Pennsylvania Experience
Open Access
- 13 November 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4), 89
- https://doi.org/10.3390/ijns6040089
Abstract
Pennsylvania started newborn screening for Pompe disease in February 2016. Between February 2016 and December 2019, 531,139 newborns were screened. Alpha-Glucosidase (GAA) enzyme activity is measured by flow-injection tandem mass spectrometry (FIA/MS/MS) and full sequencing of the GAA gene is performed as a second-tier test in all newborns with low GAA enzyme activity [<2.10 micromole/L/h]. A total of 115 newborns had low GAA enzyme activity and abnormal genetic testing and were referred to metabolic centers. Two newborns were diagnosed with Infantile Onset Pompe Disease (IOPD), and 31 newborns were confirmed to have Late Onset Pompe Disease (LOPD). The incidence of IOPD + LOPD was 1:16,095. A total of 30 patients were compound heterozygous for one pathogenic and one variant of unknown significance (VUS) mutation or two VUS mutations and were defined as suspected LOPD. The incidence of IOPD + LOPD + suspected LOPD was 1: 8431 in PA. We also found 35 carriers, 15 pseudodeficiency carriers, and 2 false positive newborns.Keywords
This publication has 33 references indexed in Scilit:
- Timing of diagnosis of patients with pompe disease: Data from the pompe registryAmerican Journal of Medical Genetics Part A, 2013
- Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe diseaseGenetics in Medicine, 2012
- Later-Onset Pompe Disease: Early Detection and Early Treatment Initiation Enabled by Newborn ScreeningThe Journal of Pediatrics, 2011
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infantsMolecular Genetics and Metabolism, 2010
- Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early TreatmentPEDIATRICS, 2009
- Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarkerGenetics in Medicine, 2009
- Elimination of Antibodies to Recombinant Enzyme in Pompe's DiseaseThe New England Journal of Medicine, 2009
- Pompe disease in infants and childrenThe Journal of Pediatrics, 2004
- Prevalence of lysosomal storage diseases in PortugalEuropean Journal of Human Genetics, 2003
- Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counsellingEuropean Journal of Human Genetics, 1999